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nticoagulant Therapy
ncreasing Use and Precautions
or a Hazardous Combination*
laine M. Hylek, MD, MPH,† David E. Solarz, MD‡
oston, Massachusetts
he prevalence of atrial fibrillation (AF) in the U.S. is
rojected to reach nearly 8 million individuals by 2020 (1).
troke prevention in AF is the most common indication for
arfarin. Approximately one-third of these individuals will
lso have coronary artery disease. Overall, the number of
arfarin prescriptions has increased from 21 million in 1998
o nearly 31 million in 2004 (2). This surge in warfarin use
as paralleled an increase in aspirin use for primary and
econdary prevention of cardiovascular disease. The in-
reased incidence of major hemorrhage, particularly among
he older patient population, is at least in part attributable to
he increased use of combination antithrombotic therapy
3). This risk was also recently highlighted in the Warfarin
ntiplatelet Vascular Evaluation trial that randomized pa-
ients with peripheral arterial disease to antiplatelet or
ombination therapy (4).
See page 56
In this issue of JACC: Cardiovascular Interventions, Ro-
acka et al. (5) report their findings from 127 consecutive
atients discharged on aspirin, a thienopyridine (clopidogrel
r ticlopidine), and warfarin after coronary stent implanta-
ion. Atrial fibrillation was the indication for warfarin in
9% of patients. The mean exposure to combination therapy
as 5.6  4.6 months. Of the 127 patients, 6 experienced a
ajor hemorrhage, 4 of which were intracranial hemor-
hages (ICH), and 3 were fatal. Most events occurred within
he first month.
This study importantly adds to the growing body of
vidence documenting the hemorrhagic risk of combined
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Clinical Epidemiology Unit and Research Unit–Section of General
nternal Medicine, and the ‡Department of Medicine, Boston University School of
edicine, Boston, Massachusetts. Dr. Hylek has received research funding froml
straZeneca and Bristol-Myers Squibb and has served in an advisory capacity to
ristol-Myers Squibb.ual antiplatelet and warfarin therapy. The hazards of triple
herapy after percutaneous coronary intervention were first
ighlighted in a retrospective analysis of 65 patients dis-
harged after coronary stenting on aspirin, clopidogrel, and
arfarin. Six patients (9.2%; 95% confidence interval [CI]
.5 to 19.0) experienced a bleeding complication; 2 met
riteria for major hemorrhage (6). Khurram et al. (7)
ubsequently published a retrospective study of 107 patients.
ajor bleeding occurred in 7 patients (6.6%); the hazard
atio of triple therapy was 5.4 compared with dual antiplate-
et therapy alone. Similar findings were reported from
inland. Among 185 patients treated for a mean of 4
onths, 18 (8.2%) sustained a major hemorrhage, including
ICH (2 related to trauma) (8).
Limitations of these studies include small sample size,
etrospective design, lack of international normalized ratio
INR) data, and small number of events that prohibits
eaningful assessment of risk. In the study by Rogacka et
l. (5), the distribution of hemorrhage raises additional
oncern. Four of the 6 major bleeds were ICH. Information
n blood pressure was not provided. The disproportionate
umber of ICH suggests incomplete ascertainment of major
xtracranial hemorrhage and a subsequent under-estimate of
he aggregate bleeding rate. It is also important to note that
lthough the authors attempt to assess differences in hem-
rrhage with different types of stents, in the absence of
andomized data, this is problematic because of confound-
ng by indication (i.e., patients at higher risk of hemorrhage
ight have preferentially received bare-metal stents to
inimize exposure to triple therapy).
The risk of upper gastrointestinal bleeding or perforated
eptic ulcer with aspirin use increases exponentially with age
9). Aspirin in combination with clopidogrel increases this
isk more than 3-fold (adjusted rate ratio [RR] 3.9, 95% CI
.8 to 5.5), and aspirin plus warfarin increases this risk more
han 6-fold (adjusted RR 6.5, 95% CI 4.3 to 9.9) (10). The
umber needed to harm with antiplatelet therapy is 33
mong high-risk female patients with a history of compli-
ated ulcer who are 80 years of age and 17 for the
omparable risk stratum in men. Nonsteroidal anti-
nflammatory drugs (NSAIDs) in combination with aspirin
reatly magnify this risk (9).
otential Strategies to Minimize
emorrhagic Complications
onsistent risk factors for major hemorrhage on warfarin
nclude older age, anticoagulation intensity, early course of
herapy, prior bleed, and concomitant antiplatelet therapy
11,12). Additional risk factors for ICH include prior stroke
nd hypertension. The clinical challenge is how best to
avigate optimal prevention of thrombosis while minimiz-
ng serious bleeding consequences. Combination antiplate-
et therapy is less effective than warfarin for stroke preven-
t
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63ion in AF (13). Improved risk stratification in AF is a
ogical first step. Current AF guidelines recommend warfa-
in for CHADS2 scores of 2 (Congestive heart failure 
 point; Hypertension  1 point; Age 75 years  1 point;
iabetes mellitus  1 point; prior Stroke/transient ischemic
ttack  2 points) and aspirin or warfarin for a CHADS2
core of 1 point (14). This point is emphasized by the
urrent study in which 2 of the patients with ICH had
HADS2 scores  0 and 1.
It is unclear to what degree hemorrhage on triple therapy
s attributable to suboptimal control of warfarin. Proven
trategies to minimize anticoagulant-related bleeding
hould be aggressively implemented, and interventions to
meliorate the hazards of antiplatelet therapy should be
nstituted (Table 1) (15). Prophylactic treatment with the
roton-pump inhibitor (PPI) lansoprazole coupled with
radication of H. pylori infection was shown to significantly
educe the risk of recurrence of ulcer complications associ-
ted with aspirin (16,17). Patients were treated with 100 mg
spirin and lansoprazole 30 mg daily after confirmed H.
ylori eradication. The risk of recurrence was 1.6% in the
PI group (95% CI 0% to 9%) and 14.8% in the placebo
roup (95% CI 7% to 26%); adjusted hazard ratio 9.6 (95%
I 1.2 to 76.1). The number needed to treat was only 7.6 to
revent 1 bleeding complication.
uture Directions
t is possible that newer anticoagulant drugs with shorter
alf-lives and a wider therapeutic window might be safer to
Table 1. Potential Strategies to Minimize Major Hemorrhage
Among Patients on Triple Therapy After Coronary Stent Implantation
1. Vigilant INR monitoring in the ﬁrst 4 weeks, especially among patients newly
starting warfarin or antiplatelet therapy
2. Judicious use of “bridging therapy” with heparin (e.g., highest-risk mechanical
prosthetic heart valve, venous thromboembolism within 3 months)
3. Improved risk stratiﬁcation for warfarin use in patients with AF
(CHADS2 score 2)
4. Increased awareness of the most potent risk factors for erratic INR control:
decompensated heart failure, enteral feeding, erratic dietary vitamin K intake,
amiodarone therapy, chemotherapy, protracted new use of high-dose
acetaminophen
5. Attention to blood pressure control with goal 130/80 mm Hg (15)
6. Prophylactic proton-pump inhibition for patients with peptic ulcer disease
7. Eradication of H. pylori in patients with peptic ulcer disease and
uninvestigated dyspepsia (17)
8. Explicit warnings regarding use of over-the-counter NSAIDs and aspirin-
containing compounds
9. Physical therapy/safety evaluation before discharge to minimize fall risk
10. There is insufﬁcient evidence to support lower INR target intensities; patients
and their caregivers need to be cognizant of the trade-offs inherent to this
strategy
AF atrial fibrillation; CHADS2 Congestive heart failure, Hypertension, Age75 years, Diabe-
tes mellitus, prior Stroke/transient ischemic attack; INR international normalized ratio; NSAIDs
 nonsteroidal anti-inflammatory drugs.se in combination with antiplatelet therapy. The balanceetween antithrombotic potency and safety will demand
mproved risk stratification particularly among individuals
75 years of age as highlighted by the recent trial that
ompared clopidogrel with prasugrel for the prevention of
n-stent thrombosis (18). The mean age of trial participants
as 61 years, and 13% were 75 years of age. Insights into
he mechanisms of enhanced gastrointestinal susceptibility
o antithrombotic therapy particularly in the elderly patient
opulation warrant further study (19). Further data, prefer-
ntially from randomized trials, are needed to better assess
he effects of staggered therapy, single versus dual antiplate-
et therapy and warfarin, and optimal duration of antiplate-
et therapy among different risk subgroups (20).
eprint requests and correspondence: Dr. Elaine M. Hylek,
oston University School of Medicine, Clinical Epidemiology
nit and Research Unit–Section of General Internal Medicine, 91
ast Concord Street, Suite 200, Boston, Massachusetts 02118.
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